

Cases from the Community: Investigators Discuss Emerging Research and Actual Patients with Colorectal Cancer

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. The Phase III KEYNOTE-177 trial comparing pembrolizumab to standard chemotherapy as first-line therapy for patients with microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (mCRC) demonstrated which of the following progression-free survival (PFS) outcomes?
 - a. No significant difference in PFS between the treatment arms
 - b. No significant difference in PFS2 (PFS on next line of therapy or death from any cause) between the treatment arms
 - c. A significant improvement in only PFS with pembrolizumab
 - d. A significant improvement in both PFS and PFS2 with pembrolizumab
2. On the basis of the results of the Phase III BEACON CRC trial, which of the following combinations recently received FDA approval for patients with previously treated mCRC harboring a BRAF V600E mutation?
 - a. Encorafenib/cetuximab/binimetinib
 - b. Encorafenib/cetuximab
 - c. Encorafenib/binimetinib/FOLFIRI
3. Which of the following adverse events is associated with the antibody-drug conjugate trastuzumab deruxtecan?
 - a. QT interval prolongation
 - b. Pneumonitis/interstitial lung disease
 - c. Dysgeusia
4. Which of the following outcomes was reported by Eric Van Cutsem and colleagues at the 2021 Gastrointestinal Cancers Symposium from the final overall survival (OS) analysis of results from the Phase II TASCO1 trial evaluating bevacizumab in combination with either TAS-102 or capecitabine as first-line therapy for patients with unresectable mCRC who were ineligible for intensive therapy?
 - a. OS was numerically better with TAS-102/bevacizumab than with capecitabine/bevacizumab
 - b. OS was numerically better with capecitabine/bevacizumab than with TAS-102/bevacizumab
 - c. No significant numerical difference in OS was reported
5. Which of the following drug types best describes the mechanism of action of napabucasin, an investigational agent being studied in the Phase III CanStem303C trial for patients with previously treated mCRC?
 - a. PD-1/PD-L1 inhibitor
 - b. Cancer stemness inhibitor
 - c. HER2 inhibitor
 - d. BRAF inhibitor